The Infliximab Free Anti-Drug Antibody ELISA is intended for the semi-quantitative determination of free anti-drug antibodies against Remicade® in human serum and EDTA plasma. Health Canada Licensed , Research Use Only. Not for Use in Diagnostic Procedures.
Health Canada Licensed, Research Use Only. Not for Use in Diagnostic Procedures.
Product Distribution
Available in North America Only
Sizes
96 Wells
Sample Types
EDTA Plasma, Serum
Inc Time Hour
Overnight
Inc Time Overnight
No
Inc Time See Protocol
No
Sample Size
100
Detection
Colorimetric
This ELISA is designed for the semi-quantitative determination of free antibodies against infliximab (e. g. REMICADE®). In a first incubation step, the free anti-infliximab antibodies from the sample are bound to the infliximab F(ab)2 fragments coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, peroxidase labeled therapy antibody is added. After another washing step, to remove all unbound substances, the solid phase is incubated with the substrate, tetramethylbenzidine (TMB). An acidic stop solution is then added. The color converts to yellow. The absorbance of the color compound is determined photometrically at 450 nm. The intensity of the color is directly proportional to the amount of bound anti-infliximab antibodies (e. g. REMICADE®) from the sample. The results are evaluated by a cut-off control.
1. What percentage of your IgE allergy testing panel consists of molecular allergens rather than allergen extracts? The ALEX2 IgE allergen panel consists of 117 extracts and 183 molecular allergens. This represents the largest panel of molecular allergens on the market, including 50 unique...
Cases of food and environmental allergies have been increasing over the last decade. While conservative estimates suggest IgE-mediated allergy affects 6-8% of children and 2-3% of adults, some estimates are as high as 30%.3, 2 Symptoms can range from mild to severe and include itching, hives,...
Food sensitivity or food intolerance involves a non-allergic response to a food or food additive. In a recent on-line survey conducted in the U.S., 24% of adults aged 18 to 79 reported a food intolerance. While a food allergy is typically mediated by IgE antibodies, adverse reactions to food...
The ALPCO Glucagon ELISA is for the quantitative determination of glucagon in human EDTA plasma. This assay was developed for ease-of-use and demonstrates superior sensitivity while eliminating cross-reactivity issues present in other commercially-available assays.
ALPCO’s automated turbidimetric solution for calprotectin testing offers enhanced efficiency without compromising clinical sensitivity or specificity. Clinicians can prioritize endoscopic evaluation for the patients that need it most and quickly put IBS patients on the right treatment path.
Join our speaker from Department of Pathology , University of Utah School of Medicine, Dr. Heather Nelson, to discuss how to validate and launch a FDA-approved assay.
Energy homeostasis is a focus of research into diabetes and obesity. Read about how our assays in this area can assist both academic and industry researchers.
Complement System Solutions for Drug Development and Clinical Research Datasheet
The complement system is essential to innate immunity from a variety of diseases. ALPCO’s full range of complement system immunoassays can drive discovery.
Melatonin Products for Sleep Disorder-Related Research Datasheet
The melatonin hormone affects the circadian rhythm and sleep-wake cycle. Find out about our immunoassays and products that explore melatonin and sleep disorders.
